MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

Several advances in the clinical portfolioApril – JuneSignificant events during the quarter · Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The analysis shows an early indication that MIV-818 works as expected, i.e. the substance has the intended liver-directed effect. · New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO. · Positive data from the investigator-initiated study evaluating the efficacy of remetinostat in basal cell carcinoma (BCC) patients presented at the SID annual meeting. · New